114 related articles for article (PubMed ID: 15824077)
1. Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?
Shai I; Rimm EB; Hankinson SE; Cannuscio C; Curhan G; Manson JE; Rifai N; Stampfer MJ; Ma J
Eur Heart J; 2005 Aug; 26(16):1633-9. PubMed ID: 15824077
[TBL] [Abstract][Full Text] [Related]
2. [Elevated levels of lipoprotein(a) are present in subjects with early ischemic cardiopathy and with a familial history of ischemic cardiopathy].
Saitta A; Castaldo M; Sardo A; Cinquegrani M; Bonaiuto M; Zema M; Gravina M; Mangano C
Minerva Med; 1999; 90(5-6):151-8. PubMed ID: 10780189
[TBL] [Abstract][Full Text] [Related]
3. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey.
Miller M; Zhan M; Havas S
Arch Intern Med; 2005 Oct; 165(18):2063-8. PubMed ID: 16216995
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease.
Imhof A; Rothenbacher D; Khuseyinova N; Hoffmeister A; Maerz W; Nauck M; Scharnagl H; Koenig W; Brenner H
Eur J Cardiovasc Prev Rehabil; 2003 Oct; 10(5):362-70. PubMed ID: 14663298
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian population.
D'Angelo A; Ruotolo G; Garancini P; Sampietro F; Mazzola G; Calori G
Haematologica; 2006 Dec; 91(12):1613-20. PubMed ID: 17145597
[TBL] [Abstract][Full Text] [Related]
6. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
7. Relation of cardiorespiratory fitness to inflammatory markers, fibrinolytic factors, and lipoprotein(a) in patients with type 2 diabetes mellitus.
Jae SY; Heffernan KS; Lee MK; Fernhall B; Park WH
Am J Cardiol; 2008 Sep; 102(6):700-3. PubMed ID: 18773991
[TBL] [Abstract][Full Text] [Related]
8. Impact of markedly elevated serum lipoprotein(a) levels (> or = 100 mg/dL) on the risk of coronary heart disease.
Murase T; Okubo M; Amemiya-Kudo M; Hiraga T; Oka J; Shimada M; Igarashi T
Metabolism; 2007 Sep; 56(9):1187-91. PubMed ID: 17697860
[TBL] [Abstract][Full Text] [Related]
9. Soluble intercellular adhesion molecules, soluble vascular cell adhesion molecules, and risk of coronary heart disease.
Shai I; Pischon T; Hu FB; Ascherio A; Rifai N; Rimm EB
Obesity (Silver Spring); 2006 Nov; 14(11):2099-106. PubMed ID: 17135628
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) and coronary heart disease in Indian population.
Singh S; Dwivedi S; Melkani GC; Rani C; Gaur SP; Mandal SK; Mahua J
J Assoc Physicians India; 1999 Dec; 47(12):1157-60. PubMed ID: 11225215
[TBL] [Abstract][Full Text] [Related]
11. Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus.
Murase T; Okubo M; Amemiya-Kudo M; Ebara T; Mori Y
Metabolism; 2008 Jun; 57(6):791-5. PubMed ID: 18502261
[TBL] [Abstract][Full Text] [Related]
12. The associations between current recommendation for physical activity and cardiovascular risks associated with obesity.
Akbartabartoori M; Lean ME; Hankey CR
Eur J Clin Nutr; 2008 Jan; 62(1):1-9. PubMed ID: 17342166
[TBL] [Abstract][Full Text] [Related]
13. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks.
Onat A; Can G; Ayhan E; Kaya Z; Hergenç G
Metabolism; 2009 Oct; 58(10):1393-9. PubMed ID: 19570555
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study.
Cushman M; Arnold AM; Psaty BM; Manolio TA; Kuller LH; Burke GL; Polak JF; Tracy RP
Circulation; 2005 Jul; 112(1):25-31. PubMed ID: 15983251
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction.
Gaeta G; Cuomo S; Capozzi G; Foglia MC; Barra S; Madrid A; Stornaiuolo V; Trevisan M
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):492-6. PubMed ID: 17962002
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers.
Rothenbacher D; Brenner H; März W; Koenig W
Eur Heart J; 2005 Aug; 26(16):1640-6. PubMed ID: 15932907
[TBL] [Abstract][Full Text] [Related]
17. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
Sarafidis PA; Lasaridis AN; Nilsson PM; Mouslech TF; Hitoglou-Makedou AD; Stafylas PC; Kazakos KA; Yovos JG; Tourkantonis AA
Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536
[TBL] [Abstract][Full Text] [Related]
18. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis.
Coutinho Tde A; Turner ST; Peyser PA; Bielak LF; Sheedy PF; Kullo IJ
Am J Hypertens; 2007 Jan; 20(1):83-9. PubMed ID: 17198917
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Lipoprotein(a) levels between elderly and middle-aged men with coronary artery disease.
Cicek H; Bayil S; Zer Y; Celik A; Geyikli I
Ann N Y Acad Sci; 2007 Apr; 1100():179-84. PubMed ID: 17460176
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk.
Pradhan AD; Shrivastava S; Cook NR; Rifai N; Creager MA; Ridker PM
Circulation; 2008 Feb; 117(6):823-31. PubMed ID: 18227386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
